FONDAparinux in patients with a plaster CAST (FONDACAST): A Multicentre, Randomized, Open-label, Controlled, Two-Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Fondaparinux versus Low-molecular-Weight Heparin (Nadroparin), in Patients Requiring Rigid or Semi-rigid Immobilization for at least 21 Days and up to 45 Days because of Isolated Non-surgical Below-Knee Injury The primary objective of the study is to demonstrate the superiority of fondaparinux 2.5 mg (1.5 mg in patients with a creatinine clearance between 30 and 50 mL/min) once daily versus LMWH (nadropari...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A proof-of-concept study of SB-751689 in men and post-menopausal women with a fractured distal radius

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

SAFE-AF: Safety of Fondaparinux in electric cardioversion of atrial fibrillation. An International, Multicentre, Randomised, Open, Controlled, Two-parallel Group, Phase II Study to Evaluate the Efficacy and Safety of ARIXTRA™ for Anticoagulation of Patients with Atrial Fibrillation undergoing Electric Cardioversion Following Transesophageal Echocardiography The primary objective of the study is to demonstrate non-inferiority of Fondaparinux once daily versus UFH/oral anticoagulation with respect to the occurrence of cerebral neurologic events, systemic t...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg OD versus Montelukast 10mg OD in Adolescent and Adult Subjects with Asthma and Seasonal Allergic Rhinitis Who are Receiving salmeterol/Fluticasone Propionate DISKUS® 100/50mcg BID or Placebo BID The main objective of this study are to show that fluticasone propionate/salmeterol combination product 100/50mcg (FSC) BID (available as Seretide DISKUS) is superior to montelukast 10mg OD (available...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE ε4-stratified subjects with mild to moderate Alzheimer’s disease (REFLECT-3) The primary objective of this study is to investigate the add-on effects of daily dosing for 48 weeks with RSG XR versus placebo on cognitive function and overall clinical response in AChEI-treated su...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy To describe the safety and efficacy of two doses of GI262570 treatment in chronic hepatitis C subjects with Genotype 1 infection, who have failed prior anti-HCV therapy, in improving immunohistochemic...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Multicentre, Two-Part, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy,Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up to 120mg Daily for 12 Weeks in the Prophylactic Treatment of Migraine The primary objective of this study is to estimate the dose-response and dose-safety relationships for GW274150 in the prophylaxis of migraine.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking Opioid Therapy for Persistent Non-Cancer Pain To compare alvimopan with placebo for efficacy in the treatment of OBD

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A double-blind, randomised, placebo controlled, three-period crossover study to investigate the pharmacodynamic effect of two CRF-1 antagonists GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS To determine the pharmacodynamic effect of single doses of GSK561679 and GW876008 on meal induced cortisol responses in patients with IBS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects To identify at least one alvimopan treatment regimen that improves spontaneous complete bowel movement (SCBM) frequency compared to placebo while maintaining an acceptable tolerability profile.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune